Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Q3 2025 value amounting to $107.7 million.

  • Centessa Pharmaceuticals' Change in Acquisitions & Divestments rose 13932.4% to $107.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.0 million, marking a year-over-year increase of 2635.19%. This contributed to the annual value of $171.8 million for FY2024, which is 2444.98% up from last year.
  • Centessa Pharmaceuticals' Change in Acquisitions & Divestments amounted to $107.7 million in Q3 2025, which was up 13932.4% from $43.2 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Change in Acquisitions & Divestments registered a high of $107.7 million during Q3 2025, and its lowest value of $25.0 million during Q4 2024.
  • For the 3-year period, Centessa Pharmaceuticals' Change in Acquisitions & Divestments averaged around $59.5 million, with its median value being $51.8 million (2023).
  • In the last 5 years, Centessa Pharmaceuticals' Change in Acquisitions & Divestments crashed by 5176.26% in 2024 and then surged by 13932.4% in 2025.
  • Over the past 3 years, Centessa Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $51.8 million in 2023, then plummeted by 51.76% to $25.0 million in 2024, then skyrocketed by 330.76% to $107.7 million in 2025.
  • Its last three reported values are $107.7 million in Q3 2025, $43.2 million for Q2 2025, and $75.1 million during Q1 2025.